摘要
Cancer cells evade immune detection via programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) interactions that inactivate T cells. PD-1/PD-L1 blockade has become an important therapy in the anti-cancer armamentarium. However, some patients do not benefit from PD-1/ PD-L1 blockade despite expressing PD-L1. Here, we screened 101 gastric cancer (GC) patients at diagnosis and 141 healthy control subjects and reported one such subpopulation of GC patients with rs17718883 polymorphism in PD-L1, resulting in a nonsense P146R mutation. We detected rs17718883 in 44% of healthy control subjects, and rs17718883 was associated with a low susceptibility to GC and better prognosis in GC patients. Structural analysis suggests that the mutation weakens the PD-1:PD-L1 interaction. This was supported by co-culture experiments of T cells, with GC cells showing that the P146R substitution results in interferon (IFN)-g secretion by T cells and enables T cells to suppress GC cell growth. Similar results with animal gastric tumor models were obtained in vivo. PD-1 monoclonal antibody treatment did not enhance the inhibitory effect of T cells on GC cells expressing PD-L1P146R in vitro or in vivo. This study suggests that rs17718883 is common and may be used as a biomarker for exclusion from PD-1/PD-L1 blockade therapy.
学科与关键词
- Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer PatientsChen, Xinhua; Zhang, Huimin; Wang, Minghao; Liu, Hao; Hu, Yanfeng; Lin, Tian; Chen, Hao; Zhao, Mingli; Chen, Tao; Li, Guoxin; Yu, Jiang*; Zhao, Liying*Frontiers in Immunology, 2022, 13: 783695.被引 7
- Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancerWang, Hao; Wu, Jing; Ling, Ruoyu; Li, Fengping; Yang, Qingbin; He, Jiayong; Lei, Xuetao; Wu, Chaorui; Zhang, Guofan; Zheng, Boyang; Peng, Yanmei; Zhang, Yihao; Chen, Hao*; Ye, Gengtai*; Li, Guoxin*Molecular Therapy-Oncolytics, 2022, 24: 547-560.被引 5
- The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 InhibitorsChen, Li; Zhao, Ruihu; Sun, Hao; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*Frontiers in Pharmacology, 2022, 13: 833584.被引 4
